- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Opinion
Video
Optimizing Long-Term Care: Physician Insights on Secondary Dermatitis Management
Author(s):
Kristine Kucera, PA-C, MPAS, DHS, discusses prescribing a PDE-4 inhibitor for Mickey Bryson's psoriasis and atopic dermatitis, emphasizing the absence of FDA-approved medications like JAK inhibitors, while Bryson underscores the challenges of daily injections, likening it to insulin use.
Video Player is loading.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
How OX40-Targeted Therapies Might Reshape Biologic Strategy in AD
Expanding Topical Non-Steroidal Options in Atopic Dermatitis to Reduce Chronic Steroid Use
Understanding the Role of OX40 in Next-Generation Eczema Therapies
Jonathan Silverberg, MD, PhD, MPH on Keeping Up With Rapid AD Developments
The Vicious Cycle of Itch, Stress, and Sleep Loss
Christopher Bunick, MD, PhD, Previews RAD 2025: Raising the Bar in Atopic Dermatitis Care
Current Unmet Needs and Emerging Solutions in Atopic Dermatitis Management
Implementation Factors Affecting Ruxolitinib Adoption in Pediatric Dermatology Practice
Regulatory Challenges and Clinical Differentiators for Pediatric Atopic Dermatitis Treatments
Evaluating the Impact of Topical JAK Inhibitors on Pediatric Atopic Dermatitis Guidelines
Related Content
